Halozyme Therapeutics (Halozyme Therapeutics) Change In Inventory : $-26.9 Mil (TTM As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Halozyme Therapeutics Change In Inventory?

Halozyme Therapeutics's change in inventory for the quarter that ended in Dec. 2023 was $1.5 Mil. It means Halozyme Therapeutics's inventory declined by $1.5 Mil from Sep. 2023 to Dec. 2023 .

Halozyme Therapeutics's change in inventory for the fiscal year that ended in Dec. 2023 was $-26.9 Mil. It means Halozyme Therapeutics's inventory increased by $26.9 Mil from Dec. 2022 to Dec. 2023 .

Halozyme Therapeutics's Total Inventories for the quarter that ended in Dec. 2023 was $127.6 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Halozyme Therapeutics's Days Inventory for the quarter that ended in Dec. 2023 was 223.79.

Inventory Turnover measures how fast the company turns over its inventory within a year. Halozyme Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.41.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Halozyme Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.56.

Halozyme Therapeutics Change In Inventory Historical Data

The historical data trend for Halozyme Therapeutics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Halozyme Therapeutics Change In Inventory Chart

Halozyme Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-6.73

-31.39

7.37

-17.48

-26.88

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Inventory	Get a 7-Day Free Trial															-2.95	-7.25	-24.74	3.63	1.47

Halozyme Therapeutics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.9 Mil.

Halozyme Therapeutics (NAS:HALO) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Halozyme Therapeutics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	128.261	/	52.298	*	365 / 4
	=	223.79

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Halozyme Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	52.298	/	128.261
	=	0.41

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Halozyme Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	128.261	/	230.039
	=	0.56

Halozyme Therapeutics Change In Inventory Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Halozyme Therapeutics Inc (NAS:HALO) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

RV7:Germany

Address

12390 El Camino Real, San Diego, CA, USA, 92130

Website

https://www.halozyme.com

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

Executives

Michael J. Labarre	officer: SVP, Chief Technical Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Helen Torley	director, officer: President and CEO	C/O ONYX PHARMACEUTICALS, INC., 249 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
James M Daly	director	INCYTE CORPORATION EXPERIMENTAL STATION, RTE 141 & HENRY CLAY RD. BLDG E336, WILMINGTON DE 19880
Jeffrey William Henderson	director	7000 CARDINAL PLACE, DUBLIN OH 43017
Nicole Labrosse	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Matthew L. Posard	director	11099 N. TORREY PINES ROAD, SUITE 100, LA JOLLA CA 92037
Akiko Moni Miyashita	director	20725 S. WESTERN AVENUE, SUITE 136, TORRANCE CA 90501
Mark Howard Snyder	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Matsui Connie	director	3030 CALLAN RD, SAN DIEGO CA 92121
Jean-pierre Bizzari	director	235 LAUREL LN, HAVERFOLD PA 19041
Kenneth J Kelley	director	1331 HILLVIEW DRIVE, MENLO PARK CA 94025
Elaine D Sun	officer: SVP, Chief Financial Officer	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Masaru Matsuda	officer: SVP, General Counsel	11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Benjamin Hickey	officer: SVP, Chief Commerical Officer	C/O MIRATI THERAPEUTICS, 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA 92121